Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis

This study has been completed.

Sponsor:

Sanofi

ClinicalTrials.gov Identifier:

NCT00811902

First Posted: December 19, 2008

Last Update Posted: February 26, 2016

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

Total duration per patient is approximately 19 weeks in total, comprising a 3-week screening period inclusive of a 2-week placebo run-in period, a 14-week treatment period, and a 2-week placebo run-out (follow-up) period

Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

18 Years and older (Adult, Senior)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Clinically definite MS (according to McDonald criteria),

Exclusion Criteria:

Multiple sclerosis exacerbation or clinical relapse within 6-month prior to the screening visit.

Subject who is not able to complete two trials of a timed 25 foot walk, with or without an assisted device,

Patients without valid V1, V2, and V4 T25-FW measurements are not eligible for randomization.

Female patients who are either pregnant or breastfeeding.

Other protocol-defined inclusion/exclusion criteria may apply.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00811902